RxDoctor Payments Data

Edgar Baselli, MD

Urology · York, PANPI 1255418885

Payments from drug & device makers

$2,060in general payments, 2019–2025

Across 115 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$435
  • AbbVie$329
  • Coloplast$250
  • Teleflex LLC$164
  • Johnson & Johnson$145
  • Pfizer$141
  • plus $597 from 19 others

What the payments were for

  • Food & beverage$1,94394%
  • Education$1176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc23$435
AbbVie(2 entities)18$329
Coloplast14$250
Teleflex LLC8$164
Johnson & Johnson9$145
Pfizer9$141
Sumitomo Pharma America, Inc.5$100
Merck3$77
Verity Pharmaceuticals Inc.3$53
Ambu Inc.4$40
Urovant Sciences Inc2$37
C. R. Bard, Inc. & Subsidiaries1$36
Rochester Medical Corporation1$32
Bayer2$31
Boston Scientific1$29
Tolmar, Inc.1$27
Laborie Medical Technologies Corp.1$22
Myovant Sciences Inc.1$21
Accord Healthcare, Inc.1$18
Tempus AI, Inc1$17
Immunitybio, Inc.1$16
Axonics, Inc.1$14
Mission Pharmacal Company1$14
Metuchen Pharmaceuticals1$12
Innovative Medical Technologies, LLC3$0

How this compares

$2,060 in reported general payments places this provider in the 45th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$258,610
Medicare patients
627
Services billed
2,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix25$72,693
MyrbetriqMirabegron23$16,813
Tamsulosin Hcl720$12,706
Dutasteride305$11,509
Trospium Chloride ErTrospium Chloride40$9,202
Darifenacin ErDarifenacin Hydrobromide12$7,517
Finasteride425$5,105
Testosterone13$3,478
Methenamine Hippurate23$2,650
Oxybutynin Chloride ErOxybutynin Chloride108$2,116
Potassium Citrate ErPotassium Citrate12$1,922
Bicalutamide61$1,555
Trospium Chloride28$1,192
Anastrozole84$925
Alfuzosin Hcl ErAlfuzosin Hcl41$759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$100$72,69325 claims
Astellas Pharma US IncMyrbetriq$435$16,81323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 596 urology providers in Pennsylvania.

Other urology in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →